MX2008002057A - Complejo de inclusion del inhibidor del factor xa con ciclodextrina. - Google Patents

Complejo de inclusion del inhibidor del factor xa con ciclodextrina.

Info

Publication number
MX2008002057A
MX2008002057A MX2008002057A MX2008002057A MX2008002057A MX 2008002057 A MX2008002057 A MX 2008002057A MX 2008002057 A MX2008002057 A MX 2008002057A MX 2008002057 A MX2008002057 A MX 2008002057A MX 2008002057 A MX2008002057 A MX 2008002057A
Authority
MX
Mexico
Prior art keywords
cyclodextrin
factor
inhibitor
inclusion complex
venous thrombosis
Prior art date
Application number
MX2008002057A
Other languages
English (en)
Inventor
Timothy M Malloy
Munir N Nassar
Uday Shankar Gogate
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2008002057A publication Critical patent/MX2008002057A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

La presente invencion proporciona una formulacion del inhibidor del Factor Xa inyectable, que incluye el inhibidor del Factor Xa de razaxaban o apixaban, un agente de solubilizacion que es una (-ciclodextrina substituida, preferentemente, el eter sulfobutilico de la (-ciclodextrina (SBE-CD) o la hidroxipropil-(-ciclodextrina (HPB-CD), y agua. Tambien es provisto un metodo para prevenir o tratar la trombosis venosa, la trombosis de las venas profundas y el sindrome coronario agudo, empleando la formulacion anterior.
MX2008002057A 2005-08-17 2006-08-16 Complejo de inclusion del inhibidor del factor xa con ciclodextrina. MX2008002057A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70907705P 2005-08-17 2005-08-17
US11/464,519 US20070191306A1 (en) 2005-08-17 2006-08-15 FACTOR Xa INHIBITOR FORMULATION AND METHOD
PCT/US2006/031801 WO2007022165A2 (en) 2005-08-17 2006-08-16 Factor xa inhibitor inclusion complex with cyclodextrin

Publications (1)

Publication Number Publication Date
MX2008002057A true MX2008002057A (es) 2008-04-16

Family

ID=37654897

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008002057A MX2008002057A (es) 2005-08-17 2006-08-16 Complejo de inclusion del inhibidor del factor xa con ciclodextrina.

Country Status (10)

Country Link
US (2) US20070191306A1 (es)
EP (1) EP1924291A2 (es)
JP (1) JP2009504746A (es)
AR (1) AR055377A1 (es)
BR (1) BRPI0614827A2 (es)
CA (1) CA2619214A1 (es)
MX (1) MX2008002057A (es)
PE (1) PE20070378A1 (es)
TW (1) TW200800270A (es)
WO (1) WO2007022165A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3106463T6 (da) 2008-10-22 2020-02-24 Array Biopharma Inc Pyrazolo[1,5-]pyrimidinforbindelse som trk-kinasehæmmer
RU2012101214A (ru) * 2009-06-16 2013-07-27 Пфайзер Инк. Лекарственные формы апиксабана
EP3251660B1 (en) 2010-02-25 2019-10-16 Bristol-Myers Squibb Holdings Ireland Unlimited Company Apixaban formulations
SG11201408511QA (en) * 2012-06-27 2015-01-29 Takeda Pharmaceutical Liquid preparations of amines and organic acids stabilized by salts
SG10201702048VA (en) * 2012-09-26 2017-04-27 Bristol Myers Squibb Holdings Ireland Apixaban liquid formulations
CN104650072B (zh) * 2013-11-18 2016-03-16 成都苑东生物制药股份有限公司 一种吡啶类衍生物
PE20181888A1 (es) * 2016-04-04 2018-12-11 Loxo Oncology Inc Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
EP3800189B1 (en) 2016-05-18 2023-06-28 Loxo Oncology, Inc. Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
CN115715770B (zh) * 2021-08-24 2024-01-26 新领医药技术(深圳)有限公司 阿哌沙班透皮贴剂及其制备方法
NL2029536B1 (en) 2021-10-27 2023-05-26 Pharma Data S A Apixaban suspension and preparation method
WO2023072967A1 (en) 2021-10-27 2023-05-04 Pharma-Data S.A. Apixaban suspension and preparation method

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407079B1 (en) * 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US4745105A (en) * 1986-08-20 1988-05-17 Griffin Charles C Low molecular weight heparin derivatives with improved permeability
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
JPH10194996A (ja) * 1996-12-25 1998-07-28 Janssen Pharmaceut Nv アシル化シクロデキストリン含有製薬組成物
US6339099B1 (en) * 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
FR2773801B1 (fr) * 1998-01-19 2000-05-12 Sanofi Sa Nouveaux pentasaccharides, procedes pour leurs preparations et compositions pharmaceutiques les contenant
JP2003509409A (ja) * 1999-09-13 2003-03-11 ３−ディメンショナル ファーマシューティカルズ， インコーポレイテッド アザシクロアルカノンセリンプロテアーゼ阻害剤
TWI331526B (en) * 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
CA2726702A1 (en) * 2001-09-21 2003-04-03 Bristol-Myers Squibb Company Lactam-containing compounds and derivatives thereof as factor xa inhibitors

Also Published As

Publication number Publication date
AR055377A1 (es) 2007-08-22
JP2009504746A (ja) 2009-02-05
CA2619214A1 (en) 2007-02-22
BRPI0614827A2 (pt) 2011-04-19
PE20070378A1 (es) 2007-05-04
WO2007022165A2 (en) 2007-02-22
US20070191306A1 (en) 2007-08-16
TW200800270A (en) 2008-01-01
EP1924291A2 (en) 2008-05-28
US20090291913A1 (en) 2009-11-26
WO2007022165A3 (en) 2007-08-23
WO2007022165B1 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
MX2008002057A (es) Complejo de inclusion del inhibidor del factor xa con ciclodextrina.
SV2009003227A (es) Composiciones de inhibidores de chk 1 ref. x-17672
NO20083143L (no) Fremgangsmate og arrangement for innmating av kjemikalier i en prosesstrom
FR2884818A1 (fr) Procede de preparation d'acide acrylique a partir de glycerol
AR037755A1 (es) Composiciones acuosas con contenido de metronidazol
AR030245A1 (es) Composiciones de gel que contienen metronidazol
NO20075865L (no) Innelukket behandlingskjemikalie og fremgangsmate for forsinket frigivelse av samme
CO5721017A2 (es) Composicion limpiadora que contiene un plomero hidrofilizado
NO20072839L (no) 4-hydroksybenzomorfaner
NO20083147L (no) Anti-OX40L-antistoffer og fremgangsmater for anvendelse av disse
WO2006096740A3 (en) An apparatus and method for employing cloning for software development
ATE514815T1 (de) Faserstrukturen mit zusatz mit geringer oberflächenenergie
ECSP077247A (es) Trans - clomifeno para el tratamiento de la hipertrofia prostatica benigna, cancer prostatico, hipogonodismo, trigliceridos elevados y alto colesterol
ATE392465T1 (de) Flüssigwaschmittel mit bleichmittelzusatz
NO20083593L (no) Anti-EphrinB2-antistoffer og fremgangsmater for anvendelse av disse
DK1495072T3 (da) Syntaktisk polyolefinsammensætning til rörbelægning
ATE483164T1 (de) Faktor xa basiertes heparin-testverfahren unter verwendung einer heparin-modifizierenden komponente
DE502005002448D1 (de) Lagervorrichtung
DE60217412D1 (de) Behandelte teppiche aus poly(trimethylenterephthalat)
CY1111768T1 (el) Νεος παραγοντας μειωσης τριγλυκεριδιου
ATE402095T1 (de) Transport- und lagergestell
ATE478063T1 (de) Verfahren zur herstellung von alkylencarbonat
NO20054998L (no) System og fremgangsmate for posisjonering av en pakning i en apenhull bronnboring
NO20080572L (no) Behandlingsfluid med forbedret avleiringshindring og fremgangsmate ved bruk av slikt fluid i underjordiske formasjoner
ES2233695T3 (es) Composicion que retarda el enrejillado.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal